Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
15.00
Dollar change
-0.11
Percentage change
-0.73
%
IndexRUT P/E- EPS (ttm)-3.40 Insider Own4.08% Shs Outstand37.16M Perf Week2.46%
Market Cap562.95M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float36.00M Perf Month15.21%
Income-126.48M PEG- EPS next Q-0.36 Inst Own95.95% Short Float11.26% Perf Quarter8.77%
Sales760.05M P/S0.74 EPS this Y60.50% Inst Trans-0.56% Short Ratio11.53 Perf Half Y39.93%
Book/sh15.24 P/B0.98 EPS next Y58.06% ROA-13.87% Short Interest4.05M Perf Year-20.38%
Cash/sh0.78 P/C19.11 EPS next 5Y9.40% ROE-20.49% 52W Range9.57 - 21.60 Perf YTD11.28%
Dividend Est.- P/FCF- EPS past 5Y- ROI-17.56% 52W High-30.56% Beta1.09
Dividend TTM- Quick Ratio1.19 Sales past 5Y13.08% Gross Margin63.90% 52W Low56.66% ATR (14)0.58
Dividend Ex-Date- Current Ratio2.65 EPS Y/Y TTM-37.83% Oper. Margin-14.50% RSI (14)62.28 Volatility2.93% 3.89%
Employees1634 Debt/Eq0.28 Sales Y/Y TTM43.54% Profit Margin-16.64% Recom2.20 Target Price20.13
Option/ShortYes / Yes LT Debt/Eq0.26 EPS Q/Q44.03% Payout- Rel Volume0.87 Prev Close15.11
Sales Surprise2.43% EPS Surprise-87.19% Sales Q/Q7.65% EarningsMay 07 BMO Avg Volume351.64K Price15.00
SMA208.27% SMA508.34% SMA2008.15% Trades Volume305,705 Change-0.73%
Date Action Analyst Rating Change Price Target Change
May-08-24Upgrade ROTH MKM Neutral → Buy $15 → $20
Oct-20-23Initiated ROTH MKM Neutral $12
Sep-12-23Downgrade Stifel Buy → Hold
Sep-12-23Downgrade BTIG Research Buy → Neutral
Jul-19-23Resumed BTIG Research Buy $27
Mar-04-22Upgrade Stifel Hold → Buy $41 → $45
Oct-20-20Initiated Stifel Hold $39
Oct-29-19Downgrade Cantor Fitzgerald Overweight → Neutral $71 → $48
Jun-01-18Initiated Cantor Fitzgerald Overweight
Jun-21-17Initiated BTIG Research Buy $52
May-16-24 07:15AM
May-13-24 11:18AM
May-09-24 07:00AM
May-08-24 01:03PM
07:43AM
03:16AM Loading…
03:16AM
May-07-24 10:38PM
01:53PM
09:34AM
08:21AM
08:00AM
Apr-26-24 06:37AM
Apr-23-24 07:00AM
Apr-16-24 07:00AM
Mar-18-24 07:00AM
11:01AM Loading…
Mar-12-24 11:01AM
Mar-07-24 01:40PM
09:53AM
Mar-06-24 08:21AM
Mar-05-24 10:52PM
04:42PM
04:03PM
Feb-29-24 07:00AM
Feb-21-24 07:00AM
Jan-18-24 07:00AM
Jan-16-24 07:00AM
Jan-09-24 08:00AM
Jan-08-24 07:00AM
Dec-27-23 08:45AM
Dec-21-23 07:00AM
07:00AM Loading…
Dec-12-23 07:00AM
Dec-11-23 09:55AM
Dec-01-23 06:16PM
Nov-29-23 12:21PM
07:00AM
Nov-28-23 11:30AM
07:00AM
Nov-27-23 10:48AM
Nov-24-23 12:28PM
Nov-23-23 09:55AM
Nov-21-23 06:30PM
Nov-13-23 09:00AM
Nov-09-23 01:43PM
Nov-08-23 05:36PM
04:07PM
09:00AM
Nov-07-23 03:59PM
Nov-06-23 07:00AM
Nov-02-23 10:00AM
Nov-01-23 10:01AM
Oct-31-23 01:48PM
Oct-29-23 09:00PM
Oct-23-23 09:00PM
03:54PM
Oct-18-23 09:00PM
07:00AM
Oct-17-23 08:33AM
Oct-13-23 09:00PM
08:40PM
08:23AM
Oct-12-23 09:10AM
07:00AM
Oct-09-23 05:25PM
01:48PM
Oct-08-23 09:00PM
Oct-06-23 09:13AM
Oct-02-23 09:00PM
Sep-27-23 09:00PM
Sep-21-23 09:22AM
Sep-20-23 07:00AM
Sep-15-23 01:03PM
Sep-12-23 02:41PM
07:03AM
Sep-01-23 09:55AM
Aug-31-23 08:00AM
Aug-29-23 09:40AM
Aug-28-23 07:00AM
Aug-23-23 07:00AM
Aug-08-23 07:15PM
06:17PM
04:08PM
Jul-25-23 07:00AM
Jun-28-23 07:00AM
Jun-21-23 08:00PM
Jun-20-23 04:01PM
11:39AM
Jun-19-23 07:00AM
Jun-01-23 07:00AM
May-09-23 05:15PM
04:10PM
04:01PM
May-04-23 07:00AM
Apr-26-23 08:00PM
04:01PM
Apr-25-23 07:00AM
Apr-06-23 09:05AM
Apr-04-23 08:43AM
Apr-03-23 08:53AM
Mar-10-23 08:26AM
Mar-08-23 10:08AM
Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kenny Kevin J.President of Global SpineJan 08 '24Option Exercise0.005,9590147,321Jan 10 04:55 PM
Hinrichs James F.DirectorSep 14 '23Buy13.477,500101,02586,153Sep 14 05:15 PM
Kenny Kevin J.President of Global SpineMay 26 '23Sale19.003,87673,644142,431May 26 05:50 PM
Kenny Kevin J.President of Global SpineMay 24 '23Sale19.004,36782,973146,307May 26 05:50 PM
Last Close
May 17 04:00PM ET
3.61
Dollar change
+0.09
Percentage change
2.56
%
OM Outset Medical Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-3.38 Insider Own8.19% Shs Outstand50.32M Perf Week17.59%
Market Cap186.71M Forward P/E- EPS next Y-1.24 Insider Trans-2.44% Shs Float47.49M Perf Month60.44%
Income-168.77M PEG- EPS next Q-0.45 Inst Own95.99% Short Float19.90% Perf Quarter5.87%
Sales125.08M P/S1.49 EPS this Y37.64% Inst Trans-4.91% Short Ratio7.04 Perf Half Y-30.04%
Book/sh1.80 P/B2.00 EPS next Y26.21% ROA-47.61% Short Interest9.45M Perf Year-82.05%
Cash/sh4.39 P/C0.82 EPS next 5Y- ROE-109.06% 52W Range1.92 - 24.13 Perf YTD-33.27%
Dividend Est.- P/FCF- EPS past 5Y-15.08% ROI-57.39% 52W High-85.04% Beta1.97
Dividend TTM- Quick Ratio5.32 Sales past 5Y202.67% Gross Margin24.61% 52W Low88.02% ATR (14)0.38
Dividend Ex-Date- Current Ratio6.42 EPS Y/Y TTM4.07% Oper. Margin-130.48% RSI (14)61.85 Volatility9.77% 11.90%
Employees480 Debt/Eq2.17 Sales Y/Y TTM5.74% Profit Margin-134.93% Recom2.25 Target Price5.64
Option/ShortYes / Yes LT Debt/Eq2.16 EPS Q/Q12.95% Payout- Rel Volume0.56 Prev Close3.52
Sales Surprise-7.19% EPS Surprise-3.64% Sales Q/Q-15.83% EarningsMay 08 AMC Avg Volume1.34M Price3.61
SMA2019.68% SMA5041.47% SMA200-40.68% Trades Volume749,331 Change2.56%
Date Action Analyst Rating Change Price Target Change
Apr-08-24Initiated BTIG Research Buy $6
Apr-05-24Upgrade CL King Neutral → Buy $6
Jan-12-24Downgrade RBC Capital Mkts Outperform → Sector Perform $14 → $6
Oct-13-23Downgrade BofA Securities Buy → Underperform $32 → $3
Aug-17-23Initiated CL King Neutral
Nov-11-22Initiated RBC Capital Mkts Outperform $23
Jul-14-22Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $20
Mar-02-22Resumed BofA Securities Buy $50
Feb-17-22Upgrade Morgan Stanley Equal-Weight → Overweight $50
Aug-18-21Initiated Cowen Outperform $70
May-13-24 06:59AM
May-10-24 03:48PM
May-09-24 03:44PM
09:42AM
03:57AM
08:58PM Loading…
May-08-24 08:58PM
05:45PM
04:02PM
May-06-24 08:48AM
08:00AM
May-03-24 09:43AM
May-01-24 04:30PM
Apr-19-24 08:30AM
Apr-18-24 01:36PM
Apr-17-24 08:30AM
08:30AM Loading…
Apr-15-24 08:30AM
Mar-13-24 04:02PM
Mar-05-24 03:34PM
Feb-26-24 09:00AM
Feb-22-24 10:51AM
07:10AM
Feb-21-24 04:49PM
04:05PM
Feb-20-24 04:25PM
Feb-05-24 10:00AM
08:30AM
Jan-08-24 08:30AM
Jan-03-24 08:30AM
Nov-29-23 04:05PM
Nov-25-23 11:43AM
06:30AM Loading…
Nov-23-23 06:30AM
Nov-16-23 02:46PM
Nov-09-23 04:05PM
Nov-07-23 04:31PM
04:05PM
Nov-02-23 10:00AM
09:35AM
Nov-01-23 09:00AM
Oct-31-23 02:00PM
10:01AM
Oct-30-23 04:05PM
Oct-27-23 11:42AM
Oct-19-23 12:31PM
Oct-17-23 05:36PM
09:35AM
Oct-16-23 08:14AM
Oct-13-23 07:21PM
09:50AM
Oct-12-23 04:05PM
Aug-29-23 04:05PM
Aug-14-23 09:24PM
Aug-02-23 05:55PM
04:05PM
Jul-13-23 08:30AM
Jul-10-23 01:09PM
10:48AM
Jun-15-23 06:56AM
Jun-06-23 04:05PM
May-30-23 07:30AM
May-05-23 06:14AM
May-04-23 09:13AM
May-03-23 06:35PM
04:05PM
Apr-30-23 05:50AM
Apr-25-23 08:30AM
Apr-23-23 07:03AM
Apr-12-23 09:05AM
08:30AM
Apr-03-23 07:01AM
Mar-25-23 08:26AM
Feb-22-23 04:05PM
Feb-17-23 04:16PM
Feb-15-23 05:54AM
Feb-14-23 12:10PM
Feb-13-23 05:45PM
04:05PM
Feb-07-23 10:00AM
Feb-06-23 10:00AM
Jan-25-23 08:30AM
Jan-09-23 08:30AM
Jan-03-23 06:10PM
Dec-23-22 05:20AM
Dec-22-22 11:21AM
Dec-20-22 04:05PM
Nov-28-22 08:00AM
Nov-26-22 05:00AM
Nov-16-22 09:09AM
Nov-11-22 01:15PM
Nov-09-22 07:24PM
04:05PM
Nov-08-22 06:25PM
04:05PM
Nov-04-22 08:30AM
Oct-27-22 09:00AM
Oct-26-22 04:05PM
Oct-24-22 06:36AM
Sep-21-22 03:24AM
Aug-30-22 04:05PM
Aug-15-22 09:00AM
Aug-09-22 09:44AM
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trigg LeslieChair and CEOMay 16 '24Sale3.535,23718,487915,804May 17 05:25 PM
Ahmed NabeelChief Financial OfficerMay 16 '24Sale3.533,91813,831318,959May 17 05:40 PM
Brottem John L.General CounselMay 16 '24Sale3.532,97210,491243,875May 17 05:36 PM
Nash MarcSVP Operations and R&DMay 16 '24Sale3.531,0973,872241,413May 17 05:38 PM
Racine Jean-OlivierChief Technology OfficerMay 10 '24Sale3.278,30627,161265,325May 10 06:19 PM
Nash MarcSVP Operations and R&DMar 15 '24Sale2.132,3915,093242,510Mar 15 06:40 PM
Ahmed NabeelChief Financial OfficerMar 01 '24Sale3.151,5844,990322,877Mar 04 04:34 PM
Trigg LeslieChair and CEOFeb 15 '24Sale3.575,32018,992833,091Feb 16 05:29 PM
Ahmed NabeelChief Financial OfficerFeb 15 '24Sale3.574,40315,719312,594Feb 16 05:24 PM
Brottem John L.General CounselFeb 15 '24Sale3.573,34111,927245,046Feb 16 05:26 PM
Williamson Steven S.Chief Commercial OfficerFeb 15 '24Sale3.572,5008,925320,347Feb 16 05:31 PM
Racine Jean-OlivierChief Technology OfficerFeb 15 '24Sale3.571,8666,662271,830Feb 16 05:28 PM
Nash MarcSVP Operations and R&DFeb 15 '24Sale3.576172,203243,100Feb 16 05:27 PM
Nash MarcSVP Operations and R&DJan 16 '24Sale429.00678290,862243,717Jan 17 08:01 PM
Trigg LeslieChair and CEOJan 16 '24Sale4.298,12634,861838,411Jan 17 08:03 PM
Ahmed NabeelChief Financial OfficerJan 16 '24Sale4.291,7267,405316,997Jan 17 07:59 PM
Brottem John L.General CounselJan 16 '24Sale4.291,4806,349248,387Jan 17 08:00 PM
Williamson Steven S.Chief Commercial OfficerJan 16 '24Sale4.299964,273322,847Jan 17 08:04 PM
Porter Stacey L.Chief People OfficerJan 16 '24Sale4.297683,29561,448Jan 17 08:02 PM
Racine Jean-OlivierChief Technology OfficerJan 16 '24Sale4.297233,102273,696Jan 17 08:03 PM
Trigg LeslieChair and CEOJan 08 '24Sale5.4914,18877,892389,099Jan 08 08:34 PM
Ahmed NabeelChief Financial OfficerJan 08 '24Sale5.4910,70958,79276,819Jan 08 08:29 PM
Brottem John L.General CounselJan 08 '24Sale5.497,34440,31948,807Jan 08 08:30 PM
Williamson Steven S.Chief Commercial OfficerJan 08 '24Sale5.497,05538,732105,939Jan 08 08:35 PM
Porter Stacey L.Chief People OfficerJan 08 '24Sale5.494,76626,16558,630Jan 08 08:31 PM
Racine Jean-OlivierChief Technology OfficerJan 08 '24Sale5.493,90521,43873,781Jan 08 08:33 PM
Williamson Steven S.Chief Commercial OfficerNov 16 '23Sale4.763,58417,060112,994Nov 17 04:22 PM
Trigg LeslieChair and CEONov 16 '23Sale4.763,17515,113403,287Nov 17 04:19 PM
Ahmed NabeelChief Financial OfficerNov 16 '23Sale4.761,6437,82187,528Nov 17 04:08 PM
Brottem John L.General CounselNov 16 '23Sale4.761,4316,81256,151Nov 17 04:15 PM
Racine Jean-OlivierChief Technology OfficerNov 16 '23Sale4.767903,76077,686Nov 17 04:18 PM
Porter Stacey L.Chief People OfficerNov 16 '23Sale4.766713,19463,396Nov 17 04:17 PM
Nash MarcSVP Operations and R&DNov 16 '23Sale4.765622,67544,757Nov 17 04:15 PM
Ahmed NabeelChief Financial OfficerSep 01 '23Sale13.615457,41789,171Sep 05 04:04 PM
Trigg LeslieChair and CEOAug 16 '23Sale15.103,02845,723406,461Aug 17 04:41 PM
Ahmed NabeelChief Financial OfficerAug 16 '23Sale15.101,56523,63289,171Aug 17 04:26 PM
Brottem John L.General CounselAug 16 '23Sale15.101,36420,59657,581Aug 17 04:28 PM
Racine Jean-OlivierChief Technology OfficerAug 16 '23Sale15.1075211,35578,475Aug 17 04:39 PM
Porter Stacey L.Chief People OfficerAug 16 '23Sale15.106389,63464,066Aug 17 04:37 PM
Williamson Steven S.Chief Commercial OfficerAug 16 '23Sale15.106359,588116,577Aug 17 04:43 PM
Nash MarcSVP Operations and R&DAug 16 '23Sale15.105358,07844,998Aug 17 04:34 PM
Trigg LeslieChair and CEOAug 01 '23Option Exercise4.1120,00082,200429,489Aug 03 04:11 PM
Trigg LeslieChair and CEOAug 01 '23Sale20.2220,000404,462409,489Aug 03 04:11 PM
Ahmed NabeelChief Financial OfficerAug 01 '23Sale20.0799019,86990,736Aug 03 04:10 PM
Brottem John L.General CounselJul 19 '23Option Exercise9.481,41513,41460,360Jul 20 04:01 PM
Brottem John L.General CounselJul 19 '23Sale20.001,41528,30058,945Jul 20 04:01 PM
Trigg LeslieChair and CEOJul 03 '23Option Exercise4.1120,00082,200429,489Jul 05 05:39 PM
Trigg LeslieChair and CEOJul 03 '23Sale20.9020,000417,944409,489Jul 05 05:39 PM
Ahmed NabeelChief Financial OfficerJul 03 '23Sale21.7099021,48391,726Jul 05 05:38 PM
Brottem John L.General CounselJun 20 '23Option Exercise9.481,41413,40560,359Jun 21 04:01 PM
Brottem John L.General CounselJun 20 '23Sale21.971,41431,06658,945Jun 21 04:01 PM
Trigg LeslieChair and CEOJun 01 '23Option Exercise4.1120,00082,200429,489Jun 01 06:08 PM
Trigg LeslieChair and CEOJun 01 '23Sale21.1020,000421,920409,489Jun 01 06:08 PM
Ahmed NabeelChief Financial OfficerJun 01 '23Sale20.8399020,62292,716Jun 01 05:31 PM